Trial Profile
An Open-label Study to Evaluate the Effect of Severe Renal Impairment on the Single-dose Pharmacokinetics of Odalasvir
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 May 2018
Price :
$35
*
At a glance
- Drugs Odalasvir (Primary)
- Indications Renal impairment
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 14 May 2018 Status changed from recruiting to completed.
- 16 Feb 2018 Planned End Date changed from 31 Dec 2017 to 1 Mar 2018.
- 16 Feb 2018 Planned primary completion date changed from 31 Dec 2017 to 1 Mar 2018.